SpringWorks gets EC orphan drug designation for NF1 treatment mirdametinib

This article was originally published here

Mirdametinib, formerly PD-0325901, is an oral and small molecule inhibitor of MEK1 and MEK2. The company has already secured orphan drug designation from the US Food and Drug

The post SpringWorks gets EC orphan drug designation for NF1 treatment mirdametinib appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply